TRAIL诱导肿瘤细胞凋亡的分子机制及其在肿瘤生物治疗中的应用前景  

Mechanism of TRAIL Induced Tumor Cell Apoptosis and Application of TRAIL Based on Tumor Therapy

作　　者：朱玲[1] 王祥喜[2] 李雪梅[2] 杨金亮[1] 

机构地区：[1]四川大学华西医院生物治疗国家重点实验室,成都610041 [2]中国科学院生物物理研究所生物大分子国家重点实验室,北京100101

出　　处：《生物物理学报》2012年第6期448-456,共9页Acta Biophysica Sinica

基　　金："重大新药创制"科技重大专项(2012ZX09103-301-030)~~

摘　　要：肿瘤坏死因子相关的凋亡诱导配体(tumor necrosis factor related apoptosis-inducingligand,TRAIL)是肿瘤坏死因子超家族成员之一,由于它能特异性诱导肿瘤细胞的凋亡而对正常细胞无毒性,因此具有被开发成治疗肿瘤的蛋白质药物的可能性。目前已经有5个与TRAIL相关的受体被鉴定出,其中,TRAILR1和TRAILR2是与诱导细胞凋亡最直接相关的受体,也是最具有前景的药物设计靶点。本文基于TRAIL蛋白及其受体复合物的三维结构分析,阐述TRAIL诱导肿瘤细胞凋亡的机制以及影响凋亡的因素和途径,对以TRAIL为靶点的肿瘤治疗的研究现状作全面综述,为探索肿瘤生物治疗的新方法和途径提供帮助。Apoptosis Tumor necrosis factor （TNF）-related apoptosis-inducing ligand （TRAIL） belongs to a small subset of proapoptotic protein ligands in the TNF superfamily. Tumor cells are significantly more sensitive to TRAIL-induced apoptosis than normal cells, so it＇s an important potential therapeutic target for the treatment of cancer. As far as now, 5 TRAIL receptors have been indentified, of which TRAILR1 and TRAILR2 are promising targets for cancer therapy. Herein we review what is known about the molecular control of TRAIL-mediated apoptosis, based on analyzing the complex structure of TRAIL with its receptor, and the potential therapeutic utility of recombinant TRAIL in antitumor study.

关 键 词：TRAIL 受体 三维结构 细胞凋亡 

分 类 号：Q71[生物学—分子生物学]